After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

Gilead Sciences (GILD) stock in focus as cancer drug Trodelvy outperforms chemotherapy in a Phase 3 trial for advanced triple ...

US antivirals major Gilead Sciences (Nasdaq: GILD) yesterday released positive top-line results from the Phase III ASCENT-03 ...

Last week saw Novavax receive full approval from the US Food and Drug Administration (FDA) for its COVID-19 vaccine, but with ...

Gilead Sciences (NasdaqGS:GILD) recently announced positive results from its ASCENT-03 study, leading to a significant role ...

Gilead Sciences, Inc. (NASDAQ:GILD) has revealed encouraging results from its ASCENT-03 clinical trial, showcasing a major ...

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast ...

For detailed financial analysis and 10+ additional ProTips, visit InvestingPro. Trodelvy’s safety profile in the trial was consistent with previous studies, with no new safety concerns identified.

From a biomarker-driven strategy to delay or avoid cystectomy, to practice-changing perioperative immunotherapy, developments ...

RedDrop, a rising star in the wellness industry for its innovative tween period care and education, today drops its newest ...

As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running ...